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The dipyridamole echocardiography test (intravenous
dipyridamole with two-dimensional echocardiographic
monitoring) was performed in 93 patients with effort
chest pain and in 10 control subjects. The test was con-
sidered positive when regional asynergy appeared after
dipyridamole administration. When negative at the low
dose (0.56 mg/kg body weight in 4 minutes), the test was
repeated on a different day with a higher dose (0.84 mgl
kg in 10 minutes). All 93 patients underwent coronary
arteriography; 72 of them had significant (>70% lu-
minal reduction) coronary artery disease.
Thirty-eight ofthe 93 patients had a positive low dose
dipyridamole echocardiography test; 15 other patients
with a negative low dose test had a positive high dose
test. All 53 patients with a positive test had significant
coronary artery disease; 12 of them had a negative ex-
The dipyridamole echocardiography test is feasible and use-
ful in patients with effort angina pectoris 0); perhaps its
major limitation is a relatively low sensitivity. In our pre-
vious study 0), the standard dose of 0.56 mg/kg body
weight in 4 minutes-employed for thallium-201 imaging
studies (2,3)-was used. Such a dose usually provides max-
imal coronary vasodilation , but there is a small risk that in
some patients the dose is insufficient (4). Conceivably, the
sensitivity of the test could be augmented by the use of a
higher dose .
We therefore performed a dipyridamole echocardiog-
raphy test at the standard dose in 93 consecutive patients
with effort chest pain who did not overlap with the patient
group of our previous study. In the patients with a negative
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ercise stress test. In relation to the presence of coronary
artery disease, the dipyridamole echocardiography test
had an overall specificityhigher than that of the exercise
stress test (100 versus 71%) and a similar overall sen-
sitivity (74 versus 69%).
The dipyridamole echocardiography test is feasible
in all patients with a good baseline echocardiogram. It
detects the site of apparent ischemia more precisely than
does an exercise stress test, and can unmask electrocar-
diographically silent ischemia. If performed in patients
with a negative low dose dipyridamole echocardlography
test, the high dose test adds sensitivity (probably by
achieving maximal dilation in patients in whom the low
dose is only partially effective), without any loss in spec-
ificity and with no apparent increase in risk.
(J Am Coli Cardiol 1986;8:848-54)
test, we repeated the test on a different day at a higher dose
of 0.84 mg/kg in 10 minutes, which should achieve maximal
coronary dilation in virtually all patients (4). In this way,
the test could theoretically detect the false negative results
due to the incomplete pharmacologic effect of the dose
employed. Available clinical experience with similar high
doses (ranging from 0 .75 to 1 mg/kg in 10 minutes) suggests
that no significant increase in risk takes place (5- 11).
Methods
Characteristics of patients. One hundred two patients
with a presumptive diagno sis of coronary artery disease,
characterized by a history of either typical or atypical effort
pain , were initially considered. Patients with unstable an-
gina , cardiac failure, congenital or valvular heart disea se,
conduction disturbances or documented cardiomyopathy were
not included in this group. Nine patients were excluded from
the set of 102 because of poor quality two-dimensional
echocardiographic baseline images . Thus, 93 patients (78
men, 15 women) with a mean age of 55 years (range 37 to
76) were enrolled in the study .
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Seventeen patients had a previous myocardial infarction
with diagnostic serum enzyme or electrocardiographic
changes, or both. Patients entering the study had discontin-
ued treatment with calcium channel blockers or nitrates, or
both, for at least 48 hours, and use of beta-adrenergic block-
ing agents for at least 15 days . All patients gave informed
consent before entering the study . Before coronary angi-
ography, all patients performed, in random order and on
different days , an exercise stress test and a dipyridamole
echocardiography test.
We also studied a control group of /0 subjects (ages 20
to 25 years). All these subjects were asymptomatic, had a
negative exercise stress test and no family history of coro-
nary artery disease.
Exercise electrocardiography. All patients performed
a multistage bicycle ergometer test , with an initial load of
25 Wand subsequent increments of 25 W every 2 minutes.
A 12 lead electrocardiogram and blood pressure determi-
nation were performed at baseline and thereafter every min-
ute . Criteria for interrupting the test were severe chest pain ,
diagnostic ST segment shift, fatigue , limiting dyspnea or
maximal predicted heart rate in absence of ischemia.
Electrocardiographic tracings were considered diagnos-
tic for myocardial ischemia when there was an ST segment
shift of at least 0 .15 mV, 0.08 second after the J point
compared with baseline.
Dipyridamole echocardiography test. Dipyridamole
was administered intravenously at a dose of 0 .56 mg/kg in
4 minutes, during continuous echocardiographic monitor-
ing, as previously described (I) . In patients with a negative
test, the test was repeated on the next day at a higher dose:
0.56 rng/kg in 4 minutes followed by 4 minutes of no dose
and then 0 .28 mg/kg in 2 minutes. The cumulative dose
was therefore 0.84 mg/kg in 10 minutes.
During the procedure, the blood pressure was recorded
each minute with a cuff sphygmomanometer. A 12 lead
electrocardiogram was performed before and every minute
after starting the intravenous infusion . Some leads (usually
V2 and V4 ) were slightly displaced to avoid interfering with
the positioning of the transducer. Aminophylline (240 mg) ,
which promptly reverses the effects of dipyridamole, was
ready for immediate use. Patients were instructed to fast for
at least 3 hours before the test and specifically to avoid
coffee and tea.
Electrocardiographic tracings were considered diagnos-
tic for myocardial ischemia when there was an ST segment
shift of at least O.15 mV, 0.08 second after the J point as
compared with baseline.
Two-dimensional echocardiograms were continuously
recorded during the dipyridamole infusion and up to 20
minutes after the end of the infusion. A commercially avail-
able wide angle phased array imaging system (Hewlett-
Packard 77020, 3.5 and 5.0 MHz transducers) was used .
In the baseline studies, all standard echocardiographic views
were obtained when possible . During the test new areas of
abnormal wall motion were identified on multiple views by
rapidly moving the ultrasound transducer through various
positions. After an optimal position for the observation of
abnormal wall motion was established , the transducer was
held stationary throughout the remainder of the study and
the recovery period.
The videotapes were analyzed by two independent ob-
servers. When there was a disagreement about the results
(positivity versus negativity), a third observer reviewed the
study and the subsequent majority judgment was binding.
None of the three observers had access to angiographic and
exercise stress test findings before interpretation of the vid-
eotapes . Segmental anatomy and wall motion were assessed
in a qualitative manner as previously reported (I). Wall
motion was graded as hyperkinetic, normal, hypokinetic,
akinetic or dyskinetic.
Positi vity of the test was linked to detection of a transient
asynergy of contraction that was absent or of lesser degree
in the baseline examination (for example, hypokinesia at
rest becoming akinesia or dyskinesia after dipyridamole
admini stration) . Any region that was already dyskinetic in
a rest condition was not considered for analysis .
/ntraobserver variability was assessed by one of the in-
vestigators repeating the evaluation of 30 studies, selected
at random, I month after the first interpretation and without
knowledge of the first evaluation .
Echocardiographic M-mode tracings , generated from a
line of view on the two-dimensional image, could be ob-
tained in 20 patients with a positive test. The percent systolic
thickening of the region involved by ischemia (as assessed
by two-dimensional echocardiography) was measured in
baseline conditions and at the peak ischemic phase (jUS!
before aminophylline injection) .
Angiographic study. All patients underwent selective
coronary arteriography, using either the Judkins or the Sones
technique. Multiple views of each vessel were filmed. A
vessel was considered to have significant obstruction if its
diameter was narrowed by 70% or more with respect to the
prestenotic tract.
Two independent observers who were unaware of echo-
cardiographic and clinical data analyzed coronary angio-
gram s for the degree of stenosis in the right, left main, left
anterior descending (or diagonal) and left circumflex (or
marginal) coronary arteries . When there was disagreement
about the degree of stenosis, a third observer reviewed the
study and the judgment was binding .
Statistical analysis. Differences between the results of
the exercise stress test and dipyridamole echocardiography
test were compared using the chi-square test; a Fisher's exact
test was utilized when appropriate . Hemodynamic and wall
motion differences before and after dipyridamole adminis-
tration were tested for significance by the paired Student
t test; values are expressed as mean rr SD.
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Results
Dipyridamole echocardiography test. Two-dimen-
sional echocardiographic studies were adequate for analysis
and of unchanged quality compared with the baseline ex-
amination in all patients. Of the 72 patients with coronary
artery disease, 38 (53%) had regional transient asynergy
(hypokinesia in 18, akinesia in 20) after the low dose of
dipyridamole. Of the remaining 34 patients with coronary
artery disease and a negative low dose test, high dose di-
pyridamole induced asynergy in 15 (hypokinesia in 7, ak-
inesia in 8) (Fig. I). In these patients, the onset of the
asynergy occurred within 0 to 5 minutes after the end of
the high dose infusion. In the 53 patients with a positive
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result in the dipyridamole echocardiography test (using both
high and low doses), the asynergy mainly involved the sep-
tum in 23 patients, inferoposterior wall in 13, anterolateral
wall in 10 and apex in 7. No patient without coronary artery
disease had a positive test (with either the low or high
dipyridamole dose).
In the 20 positive tests in which a M-mode tracing of the
ischemic region could be obtained, the percent systolic
thickening decreased from 38.7 ± 9.5% in baseline con-
ditions to 6,7 ± 7.2% at peak ischemia (p < 0.01). The
occurrence of chest pain and echocardiographic and electro-
cardiographic changes after low and high dose dipyridamole
Figure 2. Occurrence of ischemic echocardiographic changes
(ECHO), electrocardiographic changes (ECG) and angina (PAIN)
in the 21 patients (PTS) without coronary artery disease (NO CAD)
and in the 72 patients with significant coronary atherosclerosis
(CAD). Open bars represent the findings after the low dipyrid-
amole dose (0.56 mg/kg in 4 minutes), solid bars after the higher
dose (0.84 mg/kg in 10 minutes).
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Figure I. Two-dimensional pictures taken from the parasternal
long-axis view; end-diastole (E-D) is above and end-systole
(E-S) is in the middle. In the schema below, the systolic contour
(dashed lines) is superimposed on the diastolic silhouette. In basal
conditions (BASAL) a normally contracting septum (S) and pos-
terior wall (PW) are shown. Two minutes after the end of the
second infusion of dipyridamole (DIPYR) ischemia develops; the
posterior wall is almost akinetic (arrows), whereas the septum
exhibits a normal pattern of contraction.
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Heart rate (beats/min)
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
RPP (X 100) (mm Hg x beats/min)
CAD Patients With Positive High Dose Tests
(n = 15)
CAD Patients With
Low Dose High Dose Negative High Dose Tests
(negative tests) (positive tests) (n = 19)
Basal Maximal Basal Asynergy Maximal Basal Maximal
72 ± 9 84 ± 12t 77 ± 9 90 ± 12t 95 ± 24t 75 ± 10 95 ± 1St
143 ± 12 134 ± lit 143 ± 13 136 ± lit 149 ± 14* 144 ± 18 148 ± 21
84 ± 7 77 ± 6t 81 ± 9 75 ± 7t 80 ± 7 83 ± II 78 ± 12
102 ± 13 112±17t 109 ± II 121 ± 1St 141 ± 25t 107 ± 20 131 ± 18t
*p < 0.05; tp < 0.01 (significance is compared with basal). Asynergy = onset of asynergy; CAD = coronary artery disease; Maximal = maximal
hemodynamic changes; RPP = rate-pressure product.
in the two groups of patients (with and without coronary
artery disease) is summarized in Figure 2.
The assessment ofpositivity versus negativity of the 148
studies analyzed (all 93 low dose tests plus 55 tests repeated
at the higher dose) was unanimous in 142. In the remaining
six cases there was a split decision. The intraobserver agree-
ment was 100% in the 30 studies reanalyzed by the same
observer. This high level of interobserver and intraobserver
agreement was made possible by several factors: the quality
of echocardiographic tracings was as good after dipyrida-
mole as in baseline conditions; the readers agreed in advance
not to record minor degrees of hypokinesia; primary reliance
was placed on changes from baseline to peak dipyridamole;
and the investigators had previous experience in joint read-
ing (I).
Hemodynamic findings. The findings after high dose
dipyridamole in the patients with coronary artery disease
are reported in Table I. In addition, the findings after the
negative low dose test are presented for the group with a
positive high dose test.
Side effects after dipyridamole. Of the 93 patients given
low dose dipyridamole, side effects occurred in 58 (62%);
of the 55 patients given high dose dipyridamole, side effects
occurred in 38 (69%). No patient had significant arrhyth-
mias, severe hypotension or vomiting after either the low
or the high dose test. No side effects were severe and we
completed the test in all patients. Headache occurred in 29
(31%) and 20 (36%) with the low and high dose, respec-
tively; mild transient facial flushing in 20 (22%) and 15
(27%), respectively; and mild transient nausea in 12 (13%)
and 9 (16%), respectively. Patients who experienced a side
effect after the low dose usually also had this effect after
the high dose.
Findings in the control group. All the 10 control sub-
jects showed an echocardiographic pattern similar to that of
the patients with a negative test: a transient hyperkinetic
phase, reaching its peak soon after the end of the infusion,
slowly reverting to a normal contraction pattern (usually
restored 10 to 15 minutes after the end of the infusion). The
interpretation of the studies was unanimous in all 10 cases.
None of the subjects had diagnostic electrocardiographic
changes or chest pain after dipyridamole.
Exercise electrocardiography (Table 2). Six (29%) of
the 21 patients without significant coronary artery disease
had a positive exercise stress test. Fifty patients with coro-
nary artery disease had a positive exercise stress test. In 40
of these 50 patients, the dipyridamole echocardiography test
was also positive.
Table 2. Correlation of Echocardiographic and Electrocardiographic Changes With
Angiographic Findings
Group
I (controls) II III IV V
CAD 0 0 I Vessel 2 Vessel 3 Vessel
Symptoms 0 + + + +
No. of patients 10 21 24 36 12
Echo + 0(0%) 0(0%) 12 (50%) 29 (81%) 12 (100%)
EST + 0(0%) 6 (29%) 13 (54%) 26 (72%) II (92%)
CAD = coronary artery disease; Echo + = patients with positive dipyridamole echocardiography test;
EST + = patients with positive exercise stress test; Symptoms = history of effort chest pain.
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Figure 3. Relative occurrence of positivity of the dipyridamole
echocardiography test (DET) and exercise stress test (EST) in the
72 patients (PTS) with coronary artery disease. categorized ac-
cording to the numberof involved vessels. YD = vessel disease.
Twenty-two patients had coronary artery disease and a
negative exercise stress test ; 12 of them had a positive di-
pyridamole echocardiography test. None of these 22 patients
had other signs suggestive of ischemia, such as complex
ventricular ectopic activity or hypotension during the ex-
ercise stress test. Thirteen complained of mild to moderate
chest pain. Eight did not attain at least 80% of their maximal
age-predicted heart rate .
Correlations with angiographic findings (Table 2). All
patients in whom transient "all motion abnormalities were
observed had significant coronary artery disease. Each of
these patients had a significant lesion in the coronary artery
supplying the abnormal wall segment identified after di-
pyridamole. The dipyridamole echocardiography test (both
low and high dose) is significantly more specific than the
exercise stress test (100 versus 71%, P < 0.05); the exercise
stress test is more sensitive (overall sensitivity 69%) than
the low dose dipyridamole echocardiography test (53%),
whereas the high dose test (sensitivity 74% , p < 0.01 com-
pared with the low dose dipyridamole echocardiography
test) closes the sensitivity gap .
Of the 22 patients with coronary artery disease and a
negative exercise stres s test, 12 had a positive dipyridamole
echocardiography test; 4 of these patients had single, 7 had
double and I had triple vessel disease (Fig. 3). Conversely,
10 patients, of the 19 with coronary artery disease and
negative dipyridamole echocardiography test, had a positive
exercise stress test: 6 of these patients had single and 4 had
double vessel disease ( Fig . 3) .
Seventeen patients (five with a negative dipyridamole
echocardiography test and four with a negative exercise
stress test) had electrocardiographic evidence of prior myo-
cardial infarction on the electrocardiogram at rest and re-
gional asynergy on the baseline echocardiogram. Global
sensitivity for the exercise stress test (ST shift and Qwaves)
40
;so
PTS
20
10
o
lVO 2VO
o EST- DET -
• EST- DET+
~ EST+ DET+
EST+ [ 'ET -
3VO
was 75%; global sensitivity for the dipyridamole echocardi-
ography test (baseline and dipyridamole-induced asynergy)
was 81%.
Discussion
The high dose dipyridamole echocardiography test is sim-
ilar to the low dose test because it is feasible in all patients
with a good baseline echocardiogram and it can detect isch-
emic segmental wall motion abnormalities in areas supplied
by critically stenosed coronary arteries. The dipyridamole
echocardiography and exercise stress tests can detect some
patients with coronary artery disease overlooked by the other:
40 (56%) of 72 of our patients with coronary artery disease
exhibited positive results in both tests, 10 (14%) of 72 tests
were positive only in the exercise stress test and 12 (17%)
of 72 were positive only in the dipyridamole echocardiog-
raphy test. In particular, in these 12 patients with coronary
artery disease and an inconclusive exercise stress test, the
dipyridamole echocardiography test offered mechanical evi -
dence of ischemia, thereby unmasking the elusive entity of
electrocardiographically silent myocardial ischemia.
The high dose dipyridamole echocardiography test allows
one to overcome the major limitation of the low dose test,
that is. a relatively low sensitivity (53% in this study and
56% in a previous study on a different series of 66 patients)
(I). The high dose dipyridamole echocardiography test adds
sensitivity to the low dose test without any loss in specificity
and with no apparent increase in risk.
Mechanism of regional asynergy induced by high dose
dipyridamole. The most likely mechanism involved in the
development of ischemia caused by dipyridamole is adverse
redistribution of myocardial perfusion ("steal"), mostly from
subendocardium to subepicardium (2). Because the indi-
vidual response to the low dose dipyridamole is variable
(4) , the high dose could induce ischemia simply by achiev-
ing the maximal pharmacologic response, not attained with
the low dose . In these patients, the higher dose might crit-
ically increase the achieved coronary dilation and the aug-
mentation in flow might reduce the poststenotic perfusion
pressure (12). This , in turn, causes a redistribution of coro-
nary blood flow favoring subepicardial layers and may re-
duce absolute as well as relative subendocardial blood flow.
However, the higher dose of dipyridamole might also
produce hemodynamic changes favoring the development
of ischemia, especially in the presence of a maximally di-
lated coronary bed. In fact, the further decrease in aortic
pressure and increase in heart rate , although relatively triv-
ial, are possibly operating mechanisms orientated toward
the creation of unfavorable perfusion conditions .
In almost all patients with a positive high dose test, a
slight increase in rate-pressure product (at the onset of asyn-
ergy) with respect to the negative low dose test was ob-
served. It is possible then that also the small increase in
JACC Vol. 8, NO.4
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myocardial oxygen demand, as assessed by the increase in
rate-pressure product, might playa role (although probably
minor) in determining ischemia.
Feasibility of the test. In our study, we were able to
obtain adequate echocardiograms after dipyridamole in all
patients in whom an acceptable baseline study was possible.
This is in sharp contrast with the considerable difficulty in
obtaining adequate exercise echocardiograms (13-16). Sev-
eral reasons may account for this fact: 1) the patient can lie
comfortably and quietly in the position most suitable for
echo monitoring, there is no need to remain supine or stand-
ing, as in exercise stress testing, and the patient stays rel-
atively still; and 2) excessive tachycardia and particularly
hyperventilation are absent, making it easier to obtain good
quality recordings and to interpret them correctly.
Importantly, the test is not limited by physical disability,
motivation or poor physical conditioning of the patient, any
of which may severely limit or preclude the performance
of dynamic exercise. It should be obvious, however, that
dipyridamole infusion does not give information about ex-
ercise capacity and blood pressure response and that other
complex physiologic changes present during exercise (such
as the increase in cotonary tone) (17,18) are not simulated.
Another limitation ofthe dipyridamole echocardiography
test is that an adequate two-dimensional echocardiographic
study in rest conditions cannot be obtained in all patients.
In our study, 9 (9%) of 102 patients had poor quality echo-
cardiographic images at rest and, therefore, were not en-
rolled in the study. In these selected cases, other noninvasive
cardiac imaging techniques might be of some help to identify
the diagnostic end point of a transient regional asynergy
induced by dipyridamole infusion. Further studies are needed,
however, to establish this point.
Safety of the dipyridamole dose employed. No sig-
nificant arrhythmias, hypotension or other significant clin-
ical complications occurred in any of the patients tested with
the high dose of dipyridamole. The safety of the high dose
test is more substantially documented by the wide clinical ex-
perience with similar doses, ranging from 0.75 to 1 mg/kg
in 10 minutes (5-11). In a series reported by Osterspey et
al. (9), up to 500 patients were studied with a dose of 0.75
mg/kg in 10 minutes, combined with electrocardiographic
monitoring, and no significant complications were observed.
Such experience is, however, less extensive than that gained
with the lower dose, which is considered a diagnostic pro-
cedure even safer than exercise (19). It should also be noted
that during the dipyridamole echocardiography test the pa-
tient lies in the recumbent position, and therefore there is
no threat of orthostatic hypotension, the limiting factor with
thallium-201 imaging combined with high doses of dipyr-
idamole (2). Moreover, the high dose is applied only in
selected patients in whom the low dose test has proved
negative.
Last, the dipyridamole echocardiography test provides
a "mechanical" marker ofthe ischemic event. The detection
of the asynergy is an end point of the test, and this allows
us to stop the procedure without waiting for some usually
"later" markers of ischemia, such as electrocardiographic
changes, which can even be absent in some patients in the
presence of obvious ischemia assessed by echocardiog-
raphy. However, the safety of using higher doses of intra-
venous dipyridamole should be established more strongly
in a larger patient series, particularly in patients with un-
stable angina or who are in the early postinfarction period.
Ischemia after dipyridamole infusion: how frequent
an event? Our data appear to conflict with the currently
accepted view that "dipyridamole produces little, if any,
myocardial ischemia" (20). In fact, the thallium-20l di-
pyridamole test does not evoke (to be positive) myocardial
ischemia as a diagnostic end point (2,21). Furthermore, pain
and electrocardiographic changes are reported as relatively
infrequent after dipyridamole infusion. For example, Albro
et a1. (3) reported only a 3% occurrence of electrocardio-
graphic changes; Leppo et al. (22) reported that only 10%
of their patients with coronary disease had electrocardio-
graphic changes. These findings seem to conflict with the
46 and 65% occurrence of ischemic electrocardiographic
changes that we observed with the low and the high dipyr-
idamole doses, respectively.
With this evidence of a high proportion of ischemic events,
doubt could arise regarding a selection bias in the population
we studied; it should be remembered, however, that all the
patients in our study were not taking medication. In the
study by Leppo et a1. (22), the majority (85%) of the patients
with coronary artery disease were taking a beta-blocker; this
might substantially blunt the ischemic effects of dipyrida-
mole while not significantly affecting flow changes, as in-
dicated by clinical and experimental data (22,23). Further-
more, our data appear to be consistent with other studies
reporting a high incidence of ischemia, both with the lower
dose (62% prevalence of electrocardiographic ischemic
changes in a series of 30 patients with coronary artery dis-
ease studied by Pirelli et al. [24]) and with the higher dose
(0.75 mg/kg in 10 minutes) (80% positivity by electrocar-
diographic criteria or pain, or both, in a series of 396 patients
with coronary artery disease reported by Osterspey et a1.
[9]).
Conclusion. The high dose dipyridamole echocardiog-
raphy test offers valuable complementary information to the
exercise stress test in patients with effort angina pectoris.
We are deeply indebted to Christopher Shaw, MD for keen and friendly
criticism.
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